Hassan Mohamed G, Zaher Abbas R, Palomo Juan Martin, Palomo Leena
Division of Craniofacial Anomalies, Department of Orofacial Sciences, University of California San Francisco, San Francisco, CA 94143, USA.
Department of Orthodontics, Faculty of Dentistry, Alexandria University, Alexandria 21526, Egypt.
Healthcare (Basel). 2018 Nov 23;6(4):134. doi: 10.3390/healthcare6040134.
Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare.
硬骨素调节是一种新型的骨调节治疗策略。医学上针对骨骼骨质流失提出的抗硬骨素药物可能会被开发用于牙科的颌骨适应症。负责容纳牙列的牙槽骨与骨骼具有共同的骨重塑机制。操纵牙槽骨周转可作为一种治疗策略，用于治疗诸如牙周炎等疾病，在牙周炎中，疾病导致的大骨缺损是手术治疗的挑战；也可用于正畸治疗中控制牙齿位置，正畸治疗的目标是使牙齿在骨中移动。为牙科开发此类治疗方法是未来的研究和治疗方向。此外，这凸显了跨专业关系，而这正是医疗保健的未来。
